Adverse reactions to docetaxel: an active survey

Authors

  • Leandro Cabral Pereira Instituto Nacional do Câncer
  • Thaísa Amorim Nogueira Universidade Federal do Rio de Janeiro; College of Pharmacy
  • Leandro Augusto de Oliveira Barbosa Universidade Federal de São João del-Rei; School of Biochemistry
  • Sabrina Calil-Elias Federal Fluminense University; Faculty of Pharmacy
  • Selma Rodrigues de Castilho Federal Fluminense University; Faculty of Pharmacy

DOI:

https://doi.org/10.1590/S1984-82502015000300007

Abstract

The rates of breast cancer mortality remain high in Brazil. Docetaxel is a semi-synthetic taxane used to treat various tumors, particularly tumors of the breast, lung and prostate. In this study ADR that occurred in 45 docetaxel users with breast cancer were surveyed. They were identified by type, causality (Naranjo algorithm and World Health Organization categories) and, if considered probable or defined, rated for severity according to SOBRAFO proposal (2007). A total of 325 ADR were observed: 165 in the first, 137 in the second and 23 in the third cycle. Fifty seven ADR were immediate and the others, late. Fatigue and exhaustion for more than five days, classified as Grade 3 by SOBRAFO (2007), were reported as the primary late RAM. There was no significant difference in the occurrence of immediate and late ADR between cycles (p=1 and p=0.3577, respectively). The presence of a pharmacist gave the patients a better understanding of the occurrence of RAM, especially those that occur outside the hospital, between chemotherapy cycles and are often not reported to the healthcare team, creating institutional demands and reaching the goal to track, observe and correlate the RAM for each user.

Downloads

Download data is not yet available.

Downloads

Published

2015-09-01

Issue

Section

Articles

How to Cite

Adverse reactions to docetaxel: an active survey . (2015). Brazilian Journal of Pharmaceutical Sciences, 51(3), 551-559. https://doi.org/10.1590/S1984-82502015000300007